The Safety and Effectiveness of mRNA Vaccines Against SARS-CoV-2

被引:13
作者
Jamous, Yahya F. [1 ]
Alhomoud, Dalal A. [1 ]
机构
[1] King Abdulaziz City Sci & Technol, Natl Ctr Vaccine & Bioproc, Riyadh, Saudi Arabia
关键词
safety; efficacy; vaccines; mrna; sars-cov-2; COVID-19; VACCINE; HYPERSENSITIVITY; OUTCOMES; SEX;
D O I
10.7759/cureus.45602
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The coronavirus disease 2019 (COVID-19) pandemic, caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in numerous deaths worldwide, along with devastating economic disruptions, and has posed unprecedented challenges to healthcare systems around the world. In the wake of COVID-19's emergence in 2019, a variety of vaccine technologies were formulated and developed, including those that drew from the technology employed in messenger RNA (mRNA) vaccines, designed to curb the disease's transmission and manage the pandemic. mRNA vaccine has several advantages over traditional ones, and hence its development has received considerable attention recently. Researchers believe the mRNA vaccine technology will emerge as the leading technology because it is potent, inexpensive, rapidly developed, and safe. This article provides an overview of mRNA vaccines with a special focus on the efficacy and safety of the Moderna and Pfizer-BioNTech mRNA vaccines against the different variants of COVID-19 and compare them with the Oxford-AstraZeneca (viral vector) and Sinopharm (inactivated virus) vaccines. The clinical data reviewed in this article demonstrate that the currently authorized Moderna and PfizerBioNTech mRNA vaccines are highly safe and potent against different variants of COVID-19, especially in comparison with Oxford-AstraZeneca (viral vector) and Sinopharm (inactivated virus) vaccines.
引用
收藏
页数:10
相关论文
共 74 条
[1]   mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials [J].
A Feldman, Robert ;
Fuhr, Rainard ;
Smolenov, Igor ;
Ribeiro, Amilcar ;
Panther, Lori ;
Watson, Mike ;
Senn, Joseph J. ;
Smith, Mike ;
Almarsson, Orn ;
Pujar, Hari S. ;
Laska, Michael E. ;
Thompson, James ;
Zaks, Tal ;
Ciaramella, Giuseppe .
VACCINE, 2019, 37 (25) :3326-3334
[2]   Review the safety of Covid-19 mRNA vaccines: a review [J].
Anand, Pratibha ;
Stahel, Vincent P. .
PATIENT SAFETY IN SURGERY, 2021, 15 (01)
[3]   The proximal origin of SARS-CoV-2 [J].
Andersen, Kristian G. ;
Rambaut, Andrew ;
Lipkin, W. Ian ;
Holmes, Edward C. ;
Garry, Robert F. .
NATURE MEDICINE, 2020, 26 (04) :450-452
[4]  
[Anonymous], 2021, Modernabegins testing its vaccine in babies and young children
[5]  
[Anonymous], 2021, FDA AUTH PFIZ BIONTE
[6]   Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine [J].
Baden, Lindsey R. ;
El Sahly, Hana M. ;
Essink, Brandon ;
Kotloff, Karen ;
Frey, Sharon ;
Novak, Rick ;
Diemert, David ;
Spector, Stephen A. ;
Rouphael, Nadine ;
Creech, C. Buddy ;
McGettigan, John ;
Khetan, Shishir ;
Segall, Nathan ;
Solis, Joel ;
Brosz, Adam ;
Fierro, Carlos ;
Schwartz, Howard ;
Neuzil, Kathleen ;
Corey, Larry ;
Gilbert, Peter ;
Janes, Holly ;
Follmann, Dean ;
Marovich, Mary ;
Mascola, John ;
Polakowski, Laura ;
Ledgerwood, Julie ;
Graham, Barney S. ;
Bennett, Hamilton ;
Pajon, Rolando ;
Knightly, Conor ;
Leav, Brett ;
Deng, Weiping ;
Zhou, Honghong ;
Han, Shu ;
Ivarsson, Melanie ;
Miller, Jacqueline ;
Zaks, Tal .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (05) :403-416
[7]   mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach [J].
Banerji, Aleena ;
Wickner, Paige G. ;
Saff, Rebecca ;
Stone, Cosby A. ;
Robinson, Lacey B. ;
Long, Aidan A. ;
Wolfson, Anna R. ;
Williams, Paul ;
Khan, David A. ;
Phillips, Elizabeth ;
Blumenthal, Kimberly G. .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2021, 9 (04) :1423-1437
[8]   Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting [J].
Barda, Noam ;
Dagan, Noa ;
Ben-Shlomo, Yatir ;
Kepten, Eldad ;
Waxman, Jacob ;
Ohana, Reut ;
Hernan, Miguel A. ;
Lipsitch, Marc ;
Kohane, Isaac ;
Netzer, Doron ;
Reis, Ben Y. ;
Balicer, Ran D. .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (12) :1078-1090
[9]   Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses [J].
Benotmane, Ilies ;
Gautier, Gabriela ;
Perrin, Peggy ;
Olagne, Jerome ;
Cognard, Noelle ;
Fafi-Kremer, Samira ;
Caillard, Sophie .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 326 (11) :1063-1065
[10]   Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial [J].
Bergman, Peter ;
Blennow, Ola ;
Hansson, Lotta ;
Mielke, Stephan ;
Nowak, Piotr ;
Chen, Puran ;
Soderdahl, Gunnar ;
Osterborg, Anders ;
Smith, C. I. Edvard ;
Wullimann, David ;
Vesterbacka, Jan ;
Lindgren, Gustaf ;
Blixt, Lisa ;
Friman, Gustav ;
Wahren-Borgstrom, Emilie ;
Nordlander, Anna ;
Gomez, Angelica Cuapio ;
Akber, Mira ;
Valentini, Davide ;
Norlin, Anna-Carin ;
Thalme, Anders ;
Bogdanovic, Gordana ;
Muschiol, Sandra ;
Nilsson, Peter ;
Hober, Sophia ;
Lore, Karin ;
Chen, Margaret Sallberg ;
Buggert, Marcus ;
Ljunggren, Hans-Gustaf ;
Ljungman, Per ;
Aleman, Soo .
EBIOMEDICINE, 2021, 74